[Uterine leiomyomas--risk factors].

Ginekol Pol

Kliniki Ginekologii i Połoznictwa Septycznego, Collegium Medicum UJ, Kraków.

Published: December 2003

Uterine leiomyomas are benign tumours that arise from the smooth-muscle cells of the human uterus. They are clinically apparent in up to 20% of women and cause significant morbidity, including prolonged and heavy menstrual bleeding, pelvic pressure or pain and reproductive dysfunction. Surgery has been the mainstay of fibroid treatment and various minimally invasive procedures have been developed in addition to hysterectomy and abdominal myomectomy, but formation of new leiomyomas after these conservatives therapies remains a substantial problem. The pathophysiology of myomas is not well understood. We present some views of epidemiological, reproductive and environmental factors, which may stimulate myomas formation. We also present a brief survey of the literature about genetic predisposition, mutations, steroid hormone and growth factors concentration, which seems to pay an important role in fibrotic processes and angiogenesis observed during formation and growth of these tumours. New research into the basic biology of these neoplasms may add new treatment options for the future as the role of growth factors and genetic mutations in these tumours are better understood.

Download full-text PDF

Source

Publication Analysis

Top Keywords

growth factors
8
[uterine leiomyomas--risk
4
leiomyomas--risk factors]
4
factors] uterine
4
uterine leiomyomas
4
leiomyomas benign
4
benign tumours
4
tumours smooth-muscle
4
smooth-muscle cells
4
cells human
4

Similar Publications

Background And Objectives: Patients with multiple sclerosis (MS) may demonstrate better disease control when treatment is initiated on high-efficacy disease-modifying therapies (DMTs) from onset. This subgroup analysis assessed the long-term efficacy and safety profile of the high-efficacy DMT ocrelizumab (OCR) as first-line therapy for early-stage relapsing MS (RMS).

Methods: Post hoc exploratory analyses of efficacy and safety were performed in a subgroup of treatment-naive patients with RMS who received ≥1 dose of OCR in the multicenter OPERA I/II (NCT01247324/NCT01412333) studies.

View Article and Find Full Text PDF

CBX2 suppresses interferon signaling to diminish tumor immunogenicity via a noncanonical corepressor complex.

Proc Natl Acad Sci U S A

February 2025

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510050, China.

Chromobox 2 (CBX2), a crucial component of the polycomb repressive complex (PRC), has been implicated in the development of various human cancers. However, its role in the regulation of tumor immunogenicity and immune evasion remains inadequately understood. In this study, we found that ablation of CBX2 led to tumor growth inhibition, activation of the tumor immune microenvironment, and enhanced therapeutic efficacy of anti-PD1 or adoptive T cell therapies by using murine syngeneic tumor models.

View Article and Find Full Text PDF

Itch is a dominant symptom in dermatitis, and scratching promotes cutaneous inflammation, thereby worsening disease. However, the mechanisms through which scratching exacerbates inflammation and whether scratching provides benefit to the host are largely unknown. We found that scratching was required for skin inflammation in mouse models dependent on FcεRI-mediated mast cell activation.

View Article and Find Full Text PDF

Pseudoexfoliation glaucoma is a severe form of secondary open angle glaucoma and is associated with activation of the TGF-β pathway by TGF-β1. MicroRNAs (miRNAs) are small non-coding RNA species that are involved in regulation of mRNA expression and translation. To investigate what glaucomatous changes occur in the trabecular meshwork and how these changes may be regulated by miRNAs, we performed a bioinformatics analysis resulting in a miRNA-mRNA interactome.

View Article and Find Full Text PDF

Prognostic value of immune biomarkers in melanoma loco-regional metastases.

PLoS One

January 2025

Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway.

The prognosis for patients with melanoma loco-regional metastases is very heterogenous. Adjuvant PD-L1-inhibitors have improved clinical outcome for this patient group, but the prognostic impact of tumour PD-L1 expression and number of tumour infiltrating lymphocytes (TILs) is still largely unknown. Here, we investigated the impact on survival for CD3, CD8, FOXP3 and PD-L1 TIL counts and tumour PD-L1 expression in melanoma loco-regional metastases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!